Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
14.34
+0.69 (5.05%)
Nov 21, 2024, 4:00 PM EST - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 31 employees as of December 31, 2023.
Employees
31
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$931,839
Market Cap
369.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| DocGo | 4,164 |
| Canopy Growth | 1,029 |
| Revance Therapeutics | 597 |
| Sangamo Therapeutics | 405 |
| Esperion Therapeutics | 240 |
| Prime Medicine | 234 |
| KalVista Pharmaceuticals | 150 |
| Rigel Pharmaceuticals | 147 |
CTNM News
- 3 days ago - Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - Business Wire
- 8 days ago - Contineum Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 15 days ago - Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 3 months ago - Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Business Wire
- 3 months ago - Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 4 months ago - Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis - Business Wire
- 5 months ago - Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors - Business Wire
- 5 months ago - Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model - Seeking Alpha